Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorde la Hera, Belén-
dc.contributor.authorUrcelay, Elena-
dc.contributor.authorBrassat, David-
dc.contributor.authorChan, Andrew-
dc.contributor.authorVidal-Jordana, Angela-
dc.contributor.authorSalmen, Anke-
dc.contributor.authorVillar, Luisa Maria-
dc.contributor.authorAlvarez-Cermeño, José Carlos-
dc.contributor.authorIzquierdo, Guillermo-
dc.contributor.authorFernández, Oscar-
dc.contributor.authorOliver, Begoña-
dc.contributor.authorSaiz, Albert-
dc.contributor.authorAra, Jose Ramón-
dc.contributor.authorVigo, Ana G-
dc.contributor.authorArroyo, Rafael-
dc.contributor.authorMeca, Virginia-
dc.contributor.authorMalhotra, Sunny-
dc.contributor.authorFissolo, Nicolás-
dc.contributor.authorHorga, Alejandro-
dc.contributor.authorMontalban, Xavier-
dc.contributor.authorComabella, Manuel-
dc.identifier.citationde la Hera B, Urcelay E, Brassat D, Chan A, Vidal-Jordana A, Salmen A, et al. Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles. Neurol Neuroimmunol Neuroinflamm. 2014; 1(4):e47es
dc.identifier.issn2332-7812 (Online)-
dc.descriptionJournal Article;es
dc.description.abstractOBJECTIVES We aimed to investigate potential associations between human leukocyte antigen (HLA) class I and class II alleles and the development of anaphylactic/anaphylactoid reactions in patients with multiple sclerosis (MS) treated with natalizumab. METHODS HLA class I and II genotyping was performed in patients with MS who experienced anaphylactic/anaphylactoid reactions and in patients who did not develop infusion-related allergic reactions following natalizumab administration. RESULTS A total of 119 patients with MS from 3 different cohorts were included in the study: 54 with natalizumab-related anaphylactic/anaphylactoid reactions and 65 without allergic reactions. HLA-DRB1*13 and HLA-DRB1*14 alleles were significantly increased in patients who developed anaphylactic/anaphylactoid reactions (p M-H = 3 × 10(-7); odds ratio [OR]M-H = 8.96, 95% confidence interval [CI] = 3.40-23.64), with a positive predictive value (PPV) of 82%. In contrast, the HLA-DRB1*15 allele was significantly more represented in patients who did not develop anaphylactic/anaphylactoid reactions to natalizumab (p M-H = 6 × 10(-4); ORM-H = 0.2, 95% CI = 0.08-0.50), with a PPV of 81%. CONCLUSIONS HLA-DRB1 genotyping before natalizumab treatment may help neurologists to identify patients with MS at risk for developing serious systemic hypersensitivity reactions associated with natalizumab
dc.description.sponsorshipThe “Red Española de Esclerosis Múltiple (REEM)” sponsored by the FEDER-FIS, FEDER-FIS PI13/0879 and the “Ajuts per donar Suport als Grups de Recerca de Catalunya,” sponsored by the “Agència de Gestió d’Ajuts Universitaris i de Recerca” (AGAUR), Generalitat de Catalunya, Spain. The study was also funded with a FP7 grant “Best MS”: Best Escalation Treatment in Multiple Sclerosis (MS), Grant agreement no: 305477. French patients were included in the BIONAT cohort funded by the French Ministry of Health (Projet Hospitalier de Recherche Clinique, PHRC 2008 (grant agreement no: 2008-005906-38 and identifier NCT00942214) and the French MS Society (ARSEP 2007, 2008, 2010)es
dc.publisherWolters Kluwer Health/LWWes
dc.publisherAmerican Academy of Neurology-
dc.relation.ispartofNeurology Neuroimmunology & Neuroinflammationes
dc.subjectAnticuerpos monoclonales humanizadoses
dc.subjectAntígenos de histocompatibilidad clase Ies
dc.subjectPrueba de histocompatibilidades
dc.subjectEsclerosis múltiplees
dc.subject.meshMedical Subject Headings::Phenomena and Processes::Genetic Phenomena::Genetic Structures::Genome::Genome Components::Genes::Alleleses
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanizedes
dc.subject.meshMedical Subject Headings::Phenomena and Processes::Genetic Phenomena::Genotypees
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Immunologic Tests::Histocompatibility Testinges
dc.subject.meshMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humanses
dc.subject.meshMedical Subject Headings::Diseases::Respiratory Tract Diseases::Respiratory Hypersensitivityes
dc.subject.meshMedical Subject Headings::Diseases::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosises
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Odds Ratioes
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Confidence Intervalses
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Glycoproteins::Membrane Glycoproteins::Histocompatibility Antigens Class Ies
dc.titleNatalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II
dc.rights.accessRightsAcceso abiertoes
dc.contributor.authoraffiliation[de la Hera,B; Urcelay,E; Vigo.AG] Department of Immunology, Hospital Clínico San Carlos (IdISSC), Madrid, Spain. [Arroyo,R] Department of Neurology, Multiple Sclerosis Unit, Hospital Clínico San Carlos (IdISSC), Madrid, Spain. [Brassat,D] Pole des neurosciences et INSERM U1043, Université de Toulouse III, Hopital Purpan, Toulouse, France. [Chan,A; Salmen,A] Department of Neurology, St. Josef-Hospital, Ruhr University, Bochum, Germany. [Vidal-Jordana,A; Malhotra,S; Horga,A; Montalban,X; Comabella,M] Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain. [Villar,LM; Alvarez-Cermeño,JC] Departments of Neurology and Immunology, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigacion Sanitaria, Madrid, Spain. [Izquierdo,G] Hospital Universitario Virgen Macarena, Seville, Spain. [Fernández,O; Oliver,B] Unidad de Gestión Clínica de Neurociencias, Instituto de Biomedicina de Málaga (IBIMA), Hospital Universitario Regional de Málaga, Universidad de Málaga, Spain. [Saiz,A] Service of Neurology, Hospital Clínic, Universitat de Barcelona and Institut d´Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain. [Ara,JR] Department of Biochemistry, Molecular and Cellular Biology, Science Faculty, University of Zaragoza, Spain. [Meca,V] Fundación de Investigación Biomédica, Hospital Universitario de la Princesa, Madrid,
Appears in Collections:01- Artículos - IBIMA. Instituto de Investigación Biomédica de Málaga
01- Artículos - Hospital Virgen Macarena

Files in This Item:
File Description SizeFormat 
Hera_NatalizumabRelatedAnaphylactoid.pdfArtículo publicado320,82 kBAdobe PDFView/Open
Hera_Natlizumab_Table_e-1.docxTabla17,77 kBMicrosoft Word XMLView/Open
Hera_Natalizumab_Table_e-2.docTabla103 kBMicrosoft WordView/Open
Hera_Natalizumab_Table_e-3.docTabla34 kBMicrosoft WordView/Open
Hera_Natlizumab_Fig.pptFigura200,5 kBMicrosoft PowerpointView/Open

This item is licensed under a Creative Commons License Creative Commons